Cargando…
The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins
Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we sho...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172316/ https://www.ncbi.nlm.nih.gov/pubmed/15249583 http://dx.doi.org/10.1083/jcb.200403069 |
_version_ | 1782145042710790144 |
---|---|
author | Harrington, Laura S. Findlay, Greg M. Gray, Alex Tolkacheva, Tatiana Wigfield, Simon Rebholz, Heike Barnett, Jill Leslie, Nick R. Cheng, Susan Shepherd, Peter R. Gout, Ivan Downes, C. Peter Lamb, Richard F. |
author_facet | Harrington, Laura S. Findlay, Greg M. Gray, Alex Tolkacheva, Tatiana Wigfield, Simon Rebholz, Heike Barnett, Jill Leslie, Nick R. Cheng, Susan Shepherd, Peter R. Gout, Ivan Downes, C. Peter Lamb, Richard F. |
author_sort | Harrington, Laura S. |
collection | PubMed |
description | Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors. |
format | Text |
id | pubmed-2172316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21723162008-03-05 The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins Harrington, Laura S. Findlay, Greg M. Gray, Alex Tolkacheva, Tatiana Wigfield, Simon Rebholz, Heike Barnett, Jill Leslie, Nick R. Cheng, Susan Shepherd, Peter R. Gout, Ivan Downes, C. Peter Lamb, Richard F. J Cell Biol Research Articles Insulin-like growth factors elicit many responses through activation of phosphoinositide 3-OH kinase (PI3K). The tuberous sclerosis complex (TSC1-2) suppresses cell growth by negatively regulating a protein kinase, p70S6K (S6K1), which generally requires PI3K signals for its activation. Here, we show that TSC1-2 is required for insulin signaling to PI3K. TSC1-2 maintains insulin signaling to PI3K by restraining the activity of S6K, which when activated inactivates insulin receptor substrate (IRS) function, via repression of IRS-1 gene expression and via direct phosphorylation of IRS-1. Our results argue that the low malignant potential of tumors arising from TSC1-2 dysfunction may be explained by the failure of TSC mutant cells to activate PI3K and its downstream effectors. The Rockefeller University Press 2004-07-19 /pmc/articles/PMC2172316/ /pubmed/15249583 http://dx.doi.org/10.1083/jcb.200403069 Text en Copyright © 2004, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Harrington, Laura S. Findlay, Greg M. Gray, Alex Tolkacheva, Tatiana Wigfield, Simon Rebholz, Heike Barnett, Jill Leslie, Nick R. Cheng, Susan Shepherd, Peter R. Gout, Ivan Downes, C. Peter Lamb, Richard F. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title | The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title_full | The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title_fullStr | The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title_full_unstemmed | The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title_short | The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins |
title_sort | tsc1-2 tumor suppressor controls insulin–pi3k signaling via regulation of irs proteins |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172316/ https://www.ncbi.nlm.nih.gov/pubmed/15249583 http://dx.doi.org/10.1083/jcb.200403069 |
work_keys_str_mv | AT harringtonlauras thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT findlaygregm thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT grayalex thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT tolkachevatatiana thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT wigfieldsimon thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT rebholzheike thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT barnettjill thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT leslienickr thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT chengsusan thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT shepherdpeterr thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT goutivan thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT downescpeter thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT lambrichardf thetsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT harringtonlauras tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT findlaygregm tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT grayalex tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT tolkachevatatiana tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT wigfieldsimon tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT rebholzheike tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT barnettjill tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT leslienickr tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT chengsusan tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT shepherdpeterr tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT goutivan tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT downescpeter tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins AT lambrichardf tsc12tumorsuppressorcontrolsinsulinpi3ksignalingviaregulationofirsproteins |